JPRN-UMIN000022450已完成未知
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601> - Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Blood transfusion, blood products or G-CSF within 21 days at registration 2) Peripheral sensory neuropathy: Grade 1 or greater 3) Uncontrolled hypertension or diabetes; interstitial pneumonia, pulmonary fibrosis, or severe emphysema; renal failure, hepatic failure, active gastrointestinal bleeding, stroke in 3 months 4) Abnormal electrocardiogram 5) More than moderate dose of ascites, massive pleural effusion 6) Brain metastasis 7) Extensive bone metastasis 8) Multiple primary cancers 9) HBs antigen positive, HCV or HIV antibody positive
研究者
相似试验
已完成
不适用
A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)unresectable/advanced gastric cancerJPRN-UMIN000016256Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)12
已完成
不适用
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.pper rectal cancerJPRN-UMIN000015765Cancer Institute Hospital of Japanese Foundation for Cancer Research19
已完成
2 期
P II study of CapeOX therapy for small intestinal cancerunresectable or recurrent small bowel adenocarcinoma with no prior treatmentJPRN-jRCTs041180011Yasui Hirofumi17
招募中
2 期
A phase II trial of oxaliplatin, capecitabine, irinotecan (XELOXIRI) and bevacizumab as first-line therapy for patients with metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000039783Sapporo Medical University School of Medicine47
尚未招募
不适用
A feasibility study of capecitabine plus oxaliplatin (CapeOX) and S-1 plus oxaliplatin (SOX) for unresectable advanced or reccurent gastric cancerunresectable advanced or reccurent gastric cancerJPRN-UMIN000015258Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital40